Disparities in COVID-19 infection, hospitalization and death in people with schizophrenia, bipolar disorder, and major depressive disorder: A cohort study of the UK Biobank
Molecular Psychiatry — Hassan L, Peek N, Lovell K, et al. | December 08, 2021
Findings demonstrate higher risks of COVID-19 infection, hospitalization and mortality among people with schizophrenia/psychosis, bipolar disorder (BD) and major depressive disorder (MDD). Merely a proportion of these differences were accounted for by preexisting demographic features or comorbidities. Vaccination and prophylactic strategies should be prioritized in these particularly vulnerable groups.
In this study with 447,296 participants from UK Biobank, experts inquired COVID-19 related infection, hospitalization and mortality in people with severe mental illness (SMI) (schizophrenia/psychosis = 1,925, BD = 1,483 and MDD = 41,448, non-SMI = 402,440).
Unadjusted analyses revealed that people with schizophrenia/psychosis, BD, and MDD had higher odds of COVID-19 mortality, with odds ratios (ORs) 4.84, 3.76, and 1.99, respectively, vs people with no SMI.
Across all SMI groups, there were higher odds of infection and hospitalisation but especially in those with schizophrenia/psychosis (OR 1.61 and 3.47) and BD (OR 1.48 and 3.31).
Fully adjusted models showed significantly higher odds of mortality and hospitalisation in all SMI groups, though infection odds continued to be significantly higher only for MDD.
Read the full article on Molecular Psychiatry